Citations

Mayo Clinic

Showing 10 of 108602 citations.

Hyperlactatemia and poor outcome After postcardiotomy veno-arterial extracorporeal membrane oxygenation: An individual patient data meta-Analysis
Biancari, Fausto , Perrotti, Andréa , Cho, Sung‐Min , Kang, Jin Kook, Welp, Henryk , Jónsson, Kristján , Pérez, Francisco José Hernández, Alkhamees, Khalid , Loforte, Antonio , Spadaccio, Cristiano , Pettinari, Matteo , Mäkikallio, Timo , Sahli, Sebastian D. , L’Acqua, Camilla , AlBarak, Mohammed M, Laimoud, Mohamed , Samalavičius, Robertas , Alonso-Fernández-Gatta, Marta , Spahn, Donat R., Fiore, Antonio , Gatti, Giuseppe , Rosato, Stefano , L'Acqua, Camilla , Arafat, Amr A , Laimoud, Mohamed , Djordjevic, Ilija , Krasivskyi, Ihor , Cho, Sung-Min , Jónsson, Kristján , Loforte, Antonio , Pettinari, Matteo , Fiore, Antonio , Sahli, Sebastian D , Alonso-Fernandez-Gatta, Marta , Samalavicius, Robertas , Kaserer, Alexander , Ruggieri, Vito Giovanni , Kang, Jin Kook , Dalén, Magnus , Ragnarsson, Sigurður , Gatti, Giuseppe , Lechiancole, Andrea , Rosato, Stefano , Mariscalco, Giovanni , Albabtain, Monirah Abdulrahman , Djordjevic, Ilija , Krasivskyi, Ihor , Puodžiukaitė, Lina

Perfusion | April 17, 2023 | Volume: 39 | Issue: 5 | Pages: 956-965

10.1177/02676591231170978 | PMID 37066850 Get It

Introduction Postcardiotomy veno-arterial extracorporeal membrane oxygenation (V-A-ECMO) is associated with significant mortality. Identification of patients at very high risk for death is elusive and the decision to initiate V-A-ECMO is based on clinical judgment. The prognostic impact of pre-V-A-ECMO arterial lactate level in these critically ill patients has been herein evaluated. Methods A systematic review was conducted to identify studies on postcardiotomy VA-ECMO for the present individual patient data meta-analysis. Results Overall, 1269 patients selected from 10 studies were included in this analysis. Arterial lactate level at V-A-ECMO initiation was increased in patients who died during the index hospitalization compared to those who survived (9.3 vs 6.6 mmol/L, p < 0.0001). Accordingly, in hospital mortality increased along quintiles of pre-V-A-ECMO arterial lactate level (quintiles: 1, 54.9%; 2, 54.9%; 3, 67.3%; 4, 74.2%; 5, 82.2%, p < 0.0001). The best cut-off for arterial lactate was 6.8 mmol/L (in-hospital mortality, 76.7% vs. 55.7%, p < 0.0001). Multivariable multilevel mixed-effect logistic regression model including arterial lactate level significantly increased the area under the receiver operating characteristics curve (0.731, 95% CI 0.702–0.760 vs 0.679, 95% CI 0.648–0.711, DeLong test p < 0.0001). Classification and regression tree analysis showed the in-hospital mortality was 85.2% in patients aged more than 70 years with pre-V-A-ECMO arterial lactate level ≥6.8 mmol/L. Conclusions Among patients requiring postcardiotomy V-A-ECMO, hyperlactatemia was associated with a marked increase of in-hospital mortality. Arterial lactate may be useful in guiding the decision-making process and the timing of initiation of postcardiotomy V-A-ECMO.
Natural Polyphenols—Resveratrol, Quercetin, Magnolol, and β-Catechin—Block Certain Aspects of Heroin Addiction and Modulate Striatal IL-6 and TNF-α
ElShebiney, Shaimaa , Elgohary, Rania , El-Shamarka, Marwa El-Sayed , Mowaad, Noha A. , Abulseoud, Osama A.

Toxics | April 17, 2023 | Volume: 11 | Issue: 4 | Pages: 379

10.3390/toxics11040379 | PMID 37112606 Get It

We have examined the effects of four different polyphenols in attenuating heroin addiction using a conditioned place preference (CPP) paradigm. Adult male Sprague Dawley rats received heroin (alternating with saline) in escalating doses starting from 10 mg/kg, i.p. up to 80 mg/kg/d for 14 consecutive days. The rats were treated with distilled water (1 mL), quercetin (50 mg/kg/d), β-catechin (100 mg/kg/d), resveratrol (30 mg/kg/d), or magnolol (50 mg/kg/d) through oral gavage for 7 consecutive days, 30 min before heroin administration, starting on day 8. Heroin withdrawal manifestations were assessed 24 h post last heroin administration following the administration of naloxone (1 mg/kg i.p). Heroin CPP reinstatement was tested following a single dose of heroin (10 mg/kg i.p.) administration. Striatal interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) were quantified (ELISA) after naloxone-precipitated heroin withdrawal. Compared to the vehicle, the heroin-administered rats spent significantly more time in the heroin-paired chamber (p < 0.0001). Concomitant administration of resveratrol and quercetin prevented the acquisition of heroin CPP, while resveratrol, quercetin, and magnolol blocked heroin-triggered reinstatement. Magnolol, quercetin, and β-catechin blocked naloxone-precipitated heroin withdrawal and increased striatal IL-6 concentration (p < 0.01). Resveratrol administration was associated with significantly higher withdrawal scores compared to those of the control animals (p < 0.0001). The results of this study show that different polyphenols target specific behavioral domains of heroin addiction in a CPP model and modulate the increase in striatal inflammatory cytokines TNF-α and IL-6 observed during naloxone-precipitated heroin withdrawal. Further research is needed to study the clinical utility of polyphenols and to investigate the intriguing finding that resveratrol enhances, rather than attenuates naloxone-precipitated heroin withdrawal.
The Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis
Khosla, Atulya Aman , Saunders, Hollie , Helgeson, Scott A. , Hikida, Hiroshi Dean , Aslam, Nabeel , Salem, Fadi , Albadri, Sam , Baig, Hassan , Helgeson, Scott A , Hikida, Hiroshi , Salem, Fadi E , Baig, Hassan Z

Case Reports in Pulmonology | April 15, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-4

10.1155/2023/1461011 | PMID 37095760 Get It

Hydralazine is a vasodilator used for the management of hypertension, heart failure, and hypertensive emergencies in pregnancy. It has been implicated in the causation of drug-induced lupus erythematosus (DLE) and rarely with ANCA-associated vasculitis (AAV), which may present as a pulmonary-renal syndrome and be rapidly fatal. Herein, we describe a case of hydralazine-associated AAV presenting as acute kidney injury with the use of early bronchoalveolar lavage (BAL) with serial aliquots to aid with diagnosis. Our case highlights how, in the correct clinical setting, BAL can act as a rapid diagnostic test to help guide quicker treatment to allow for better patient outcomes.
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection
Louie, Thomas , Golan, Yoav , Khanna, Sahil , Bobilev, Dmitri, Erpelding, Nathalie, Fratazzi, Candida, Carini, Meg, Menon, Rajita , Ruisi, Mary, Faith, Jeremiah J. , Olle, Bernat , Li, Minran, Silber, Jeffrey L. , Pardi, Darrell S. , Norman, Jason M.

JAMA | April 15, 2023 | Volume: 329 | Issue: 16 | Pages: 1356

10.1001/jama.2023.4314 | PMID 37060545 Get It

ImportanceThe effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown.ObjectiveTo determine the efficacy of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, in adults at high risk for CDI recurrence. The primary objective was to determine the recommended VE303 dosing for a phase 3 trial.Design, Setting, and ParticipantsPhase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. The study included 79 participants aged 18 years or older who were diagnosed with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence (defined as aged ≥75 years or ≥65 years with ≥1 risk factors: creatinine clearance &amp;lt;60 mL/min/1.73 m2, proton pump inhibitor use, remote [&amp;gt;6 months earlier] CDI history).InterventionsParticipants were randomly assigned to high-dose VE303 (8.0 × 109 colony-forming units [CFUs]) (n = 30), low-dose VE303 (1.6 × 109 CFUs) (n = 27), or placebo capsules (n = 22) orally once daily for 14 days.Main Outcomes and MeasuresThe primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. The primary efficacy end point was analyzed in 3 prespecified analyses, using successively broader definitions for an on-study CDI recurrence: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea consistent with CDI plus a toxin-positive, polymerase chain reaction–positive, or toxigenic culture–positive stool sample; and (3) diarrhea consistent with CDI plus laboratory confirmation or (in the absence of a stool sample) treatment with a CDI-targeted antibiotic.ResultsBaseline characteristics were similar across the high-dose VE303 (n = 29; 1 additional participant excluded from efficacy analysis), low-dose VE303 (n = 27), and placebo (n = 22) groups. The participants’ median age was 63.5 years (range, 24-96); 70.5% were female; and 1.3% were Asian, 1.3% Black, 2.6% Hispanic, and 96.2% White. CDI recurrence rates through week 8 (using the efficacy analysis 3 definition) were 13.8% (4/29) for high-dose VE303, 37.0% (10/27) for low-dose VE303, and 45.5% (10/22) for placebo (P = .006, high-dose VE303 vs placebo).Conclusions and RelevanceAmong adults with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.Trial RegistrationClinicalTrials.gov Identifier: NCT03788434
Incidentally Discovered Right Atrial Mass: A Rare and Unexpected Etiology
Sykora, Daniel , Chaliki, Hari P. , Cummings, Kristopher W. , Stanton, Melissa, Scott, Luis R. , Sell-Dottin, Kristen, Stanton, Melissa L, Sell‐Dottin, Kristen

Texas Heart Institute Journal | April 15, 2023 | Volume: 50 | Issue: 2 | Pages: No page available

10.14503/thij-21-7735 | PMID 37060553 Get It

Abstract Primary cardiac sarcoma is a rare type of intracardiac mass. This report describes a patient with atrial flutter who had a new right atrial mass incidentally discovered on transesophageal echocardiography. A thrombus was suspected based on radiographic appearance, but there was minimal change with anticoagulation. The mass was resected and found to be an undifferentiated pleomorphic cardiac sarcoma, an uncommon sub-type within the already rare category of primary cardiac neoplasms. This report highlights the importance of considering primary malignancy and thoroughly correlating radiographic and clinical evidence during the diagnostic workup of patients with intracardiac masses.
Impact of opioids on esophageal motility
Snyder, Diana L. , Vela, Marcelo F.

Neurogastroenterology & Motility | April 15, 2023 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/nmo.14587 | PMID 37060333 Get It

AbstractOpioids are well known to cause adverse effects on the gastrointestinal tract including nausea, vomiting, and constipation. Data regarding how opioids affect the esophagus are more limited. Opioid‐induced esophageal dysfunction (OIED) is a clinical syndrome defined by chronic opioid use (≥3 months), esophageal symptoms (mainly dysphagia), and esophageal motility abnormalities diagnosed by manometry including achalasia type III, hypercontractile esophagus, distal esophageal spasm, and esophagogastric junction outflow obstruction. Up until now, the effect of opioids on esophageal motility assessed by the functional lumen imaging probe (FLIP) had not been described. In this issue of NGM, Patel et al. report that FLIP assessment in patients with esophageal symptoms showed that chronic opioid users have a significant increase in repetitive retrograde contractions, but no significant reduction in distensibility at the esophagogastric junction compared to non‐users. Additionally, perceptive symptoms were higher, and quality of life metrics were lower in the chronic opioid users. This review article will discuss our current understanding of OIED and provide context for this latest study in chronic opioid users. Further investigation with larger prospective studies is needed to understand the pathophysiology, diagnosis, and management of OIED.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes
Weiner, Adam B. , Hakansson, Alex, Zhao, Xin , Proudfoot, James A. , Ho, Julian, Zhang, JJ H., Li, Eric V. , Karnes, R. Jeffrey , Kishan, Amar U. , Reiter, Robert E. , Hamid, Anis , Ross, Ashely E., Spratt, Daniel E. , Chua, Melvin L.K. , Sweeney, Christopher J. , Schaeffer, Edward M. , Li, Eric V , Hamid, Anis A , Spratt, Daniel E , Sweeney, Christopher , Chua, Melvin L K , Liu, Yang , Den, Robert B. , Ross, Ashely E., Tran, Phuoc T , Davicioni, Elai , Attard, Gerhardt , Lotan, Tamara Levin , Zhang, JJ H.

Cancer | April 15, 2023 | Volume: 129 | Issue: 14 | Pages: 2169-2178

10.1002/cncr.34790 | PMID 37060201 Get It

AbstractBackgroundProstate cancer (PCa) is a clinically heterogeneous disease. The creation of an expression‐based subtyping model based on prostate‐specific biological processes was sought.MethodsUnsupervised machine learning of gene expression profiles from prospectively collected primary prostate tumors (training, n = 32,000; evaluation, n = 68,547) was used to create a prostate subtyping classifier (PSC) based on basal versus luminal cell expression patterns and other gene signatures relevant to PCa biology. Subtype molecular pathways and clinical characteristics were explored in five other clinical cohorts.ResultsClustering derived four subtypes: luminal differentiated (LD), luminal proliferating (LP), basal immune (BI), and basal neuroendocrine (BN). LP and LD tumors both had higher androgen receptor activity. LP tumors also had a higher expression of cell proliferation genes, MYC activity, and characteristics of homologous recombination deficiency. BI tumors possessed significant interferon γactivity and immune infiltration on immunohistochemistry. BN tumors were characterized by lower androgen receptor activity expression, lower immune infiltration, and enrichment with neuroendocrine expression patterns. Patients with LD tumors had less aggressive tumor characteristics and the longest time to metastasis after surgery. Only patients with BI tumors derived benefit from radiotherapy after surgery in terms of time to metastasis (hazard ratio [HR], 0.09; 95% CI, 0.01–0.71; n = 855). In a phase 3 trial that randomized patients with metastatic PCa to androgen deprivation with or without docetaxel (n = 108), only patients with LP tumors derived survival benefit from docetaxel (HR, 0.21; 95% CI, 0.09–0.51).ConclusionsWith the use of expression profiles from over 100,000 tumors, a PSC was developed that identified four subtypes with distinct biological and clinical features.Plain language summary Prostate cancer can behave in an indolent or aggressive manner and vary in how it responds to certain treatments. To differentiate prostate cancer on the basis of biological features, we developed a novel RNA signature by using data from over 100,000 prostate tumors—the largest data set of its kind. This signature can inform patients and physicians on tumor aggressiveness and susceptibilities to treatments to help personalize cancer management.
Seizure occurrence is linked to multiday cycles in diverse physiological signals
Gregg, Nicholas M. , Attia, Tal Pal , Nasseri, Mona , Karoly, Philippa J. , Cui, Jie , Stirling, Rachel E. , Viana, Pedro F. , Nurse, Ewan S. , Cook, Mark , Richardson, Mark P. , Brinkmann, Benjamin H. , Pal Attia, Tal , Joseph, Boney , Karoly, Phillipa J , Cui, Jie , Stirling, Rachel E , Viana, Pedro F , Richner, Thomas J, Nurse, Ewan , Schulze-Bonhage, Andreas , Cook, Mark J , Worrell, Gregory A , Richardson, Mark P , Freestone, Dean R , Brinkmann, Benjamin H , Gregg, Nicholas M , Joseph, Boney , Richner, Thomas J. , Schulze‐Bonhage, Andreas , Worrell, Gregory A. , Freestone, Dean R.

Epilepsia | April 15, 2023 | Volume: 64 | Issue: 6 | Pages: 1627-1639

10.1111/epi.17607 | PMID 37060170 Get It

Abstract Objective The factors that influence seizure timing are poorly understood, and seizure unpredictability remains a major cause of disability. Work in chronobiology has shown that cyclical physiological phenomena are ubiquitous, with daily and multiday cycles evident in immune, endocrine, metabolic, neurological, and cardiovascular function. Additionally, work with chronic brain recordings has identified that seizure risk is linked to daily and multiday cycles in brain activity. Here, we provide the first characterization of the relationships between the cyclical modulation of a diverse set of physiological signals, brain activity, and seizure timing. Methods In this cohort study, 14 subjects underwent chronic ambulatory monitoring with a multimodal wrist‐worn sensor (recording heart rate, accelerometry, electrodermal activity, and temperature) and an implanted responsive neurostimulation system (recording interictal epileptiform abnormalities and electrographic seizures). Wavelet and filter–Hilbert spectral analyses characterized circadian and multiday cycles in brain and wearable recordings. Circular statistics assessed electrographic seizure timing and cycles in physiology. Results Ten subjects met inclusion criteria. The mean recording duration was 232 days. Seven subjects had reliable electroencephalographic seizure detections (mean = 76 seizures). Multiday cycles were present in all wearable device signals across all subjects. Seizure timing was phase locked to multiday cycles in five (temperature), four (heart rate, phasic electrodermal activity), and three (accelerometry, heart rate variability, tonic electrodermal activity) subjects. Notably, after regression of behavioral covariates from heart rate, six of seven subjects had seizure phase locking to the residual heart rate signal. Significance Seizure timing is associated with daily and multiday cycles in multiple physiological processes. Chronic multimodal wearable device recordings can situate rare paroxysmal events, like seizures, within a broader chronobiology context of the individual. Wearable devices may advance the understanding of factors that influence seizure risk and enable personalized time‐varying approaches to epilepsy care.
Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition
Pinto, Marcus Vinícius , França, Marcondes C. , Gonçalves, Marcus Vinícius Magno , Machado‐Costa, Marcela Câmara , Gondim, Francisco de Assis Aquino , Marrone, Carlo Domênico , Martínez, Alberto , Moreira, Carolina Lavigne , Nascimento, Osvaldo J. M. , Covaleski, Anna Paula Paranhos Miranda , Pupe, Camila , Rotta, Francisco Tellechea , Scola, Rosana Hermínia , Marques, Wilson , França, Marcondes Cavalcante , Freitas, Marcos Raimundo Gomes de , Gondim, Francisco de Assis Aquino , Marrone, Carlo Domenico , Martinez, Alberto Rolim Muro , Moreira, Carolina Lavigne , Nascimento, Osvaldo J M , Covaleski, Anna Paula Paranhos , Oliveira, Acary Souza Bulle de , Pupe, Camila Castelo Branco , Rodrigues, Marcia Maria Jardim , Rotta, Francisco Tellechea , Scola, Rosana Herminia , Marques, Wilson , Waddington-Cruz, Márcia , Pinto, Marcus V , Waddington‐Cruz, Márcia

Arquivos de Neuro-Psiquiatria | April 14, 2023 | Volume: 81 | Issue: 03 | Pages: 308-321

10.1055/s-0043-1764412 | PMID 37059440 Get It

AbstractHereditary transthyretin amyloidosis with peripheral neuropathy (ATTRv-PN) is an autosomal dominant inherited sensorimotor and autonomic polyneuropathy with over 130 pathogenic variants identified in the TTR gene. Hereditary transthyretin amyloidosis with peripheral neuropathy is a disabling, progressive and life-threatening genetic condition that leads to death in ∼ 10 years if untreated. The prospects for ATTRv-PN have changed in the last decades, as it has become a treatable neuropathy. In addition to liver transplantation, initiated in 1990, there are now at least 3 drugs approved in many countries, including Brazil, and many more are being developed. The first Brazilian consensus on ATTRv-PN was held in the city of Fortaleza, Brazil, in June 2017. Given the new advances in the area over the last 5 years, the Peripheral Neuropathy Scientific Department of the Brazilian Academy of Neurology organized a second edition of the consensus. Each panelist was responsible for reviewing the literature and updating a section of the previous paper. Thereafter, the 18 panelists got together virtually after careful review of the draft, discussed each section of the text, and reached a consensus for the final version of the manuscript.
Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials
Bhatt, Vijaya Raj , Ulrich, Angela M. , Uy, Geoffrey L. , Stone, Richard M. , Stock, Wendy , Ojelabi, Michael Olayiwola , Yin, Jun , Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Baer, Maria R. , Chow, Selina , Jatoi, Aminah , Ojelabi, Michael O , Klepin, Heidi D , Le-Rademacher, Jennifer G , Stock, Wendy , Bhatt, Vijaya Raj , Uy, Geoffrey , Klepin, Heidi D. , Le‐Rademacher, Jennifer

JCO Oncology Practice | April 14, 2023 | Volume: 19 | Issue: 6 | Pages: e877-e891

10.1200/op.22.00822 | PMID 37058684 Get It

PURPOSE: Clinical trials are important for managing older patients with AML. We investigated differences in outcomes of older patients with AML on the basis of whether patients participated in intensive chemotherapy trials at community versus academic cancer centers. METHODS: We used data from the Alliance for Clinical Trials in Oncology phase III trials that enrolled patients age ≥ 60 years with newly diagnosed AML between 1998 and 2002 in the Cancer and Leukemia Group B (CALGB) 9720 trial and between 2004 and 2006 in the CALGB 10201 trial. Centers funded by the NCI Community Oncology Research Program were identified as community cancer centers; others were designated as academic cancer centers. Logistic regression models and Cox proportional hazards models were used to compare 1-month mortality and overall survival (OS) by center type. RESULTS: Seventeen percent of the 1,170 patients were enrolled in clinical trials in community cancer centers. The study results demonstrated comparable rates of grade ≥3 adverse events (97% v 93%), 1-month mortality (19.1% v 16.1%), and OS (43.9% v 35.7% at 1 year) between community versus academic cancer centers, respectively. After adjusting for covariates, 1-month mortality (odds ratio, 1.40; 95% CI, 0.92 to 2.12; P = .11) and OS (hazard ratio, 1.04; 95% CI, 0.88 to 1.22; P = .67) were not statistically different among patients treated in community versus academic cancer centers. CONCLUSION: An older patient population, who have complex health care needs, can be successfully treated on intensive chemotherapy trials in select community cancer centers with outcomes comparable with that achieved at academic cancer centers.